Phathom Pharmaceuticals, Inc.
PHAT
$10.38
$0.100.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.50M | 28.52M | 29.66M | 16.35M | 7.32M |
| Cost of Revenue | 5.04M | 3.72M | 3.82M | 2.36M | 1.38M |
| Gross Profit | 34.47M | 24.80M | 25.85M | 14.00M | 5.95M |
| SG&A Expenses | 85.31M | 94.47M | 76.68M | 76.10M | 75.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.43M | 107.38M | 89.08M | 87.15M | 84.62M |
| Operating Income | -59.92M | -78.86M | -59.42M | -70.80M | -77.30M |
| Income Before Tax | -75.81M | -94.32M | -74.45M | -85.58M | -91.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.81M | -94.32M | -74.45M | -85.58M | -91.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.81M | -94.32M | -74.45M | -85.58M | -91.45M |
| EBIT | -59.92M | -78.86M | -59.42M | -70.80M | -77.30M |
| EBITDA | -59.75M | -78.69M | -59.22M | -70.61M | -77.10M |
| EPS Basic | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 |
| Normalized Basic EPS | -0.65 | -0.82 | -0.66 | -0.83 | -0.98 |
| EPS Diluted | -1.05 | -1.31 | -1.05 | -1.32 | -1.56 |
| Normalized Diluted EPS | -0.65 | -0.82 | -0.66 | -0.83 | -0.98 |
| Average Basic Shares Outstanding | 72.47M | 71.97M | 71.04M | 64.63M | 58.56M |
| Average Diluted Shares Outstanding | 72.47M | 71.97M | 71.04M | 64.63M | 58.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |